669 related articles for article (PubMed ID: 26285606)
1. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.
Deng Q; Tang DG
Endocr Relat Cancer; 2015 Dec; 22(6):T209-20. PubMed ID: 26285606
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel androgen receptor target genes in prostate cancer.
Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
[TBL] [Abstract][Full Text] [Related]
4. [Prostate cancer and apoptosis].
Mayora A; Arvelo F
Invest Clin; 2011 Dec; 52(4):376-96. PubMed ID: 22523847
[TBL] [Abstract][Full Text] [Related]
5. New insights into prostate cancer stem cells.
Chen X; Rycaj K; Liu X; Tang DG
Cell Cycle; 2013 Feb; 12(4):579-86. PubMed ID: 23370446
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
7. The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression.
Long MD; Singh PK; Russell JR; Llimos G; Rosario S; Rizvi A; van den Berg PR; Kirk J; Sucheston-Campbell LE; Smiraglia DJ; Campbell MJ
Oncogene; 2019 Jan; 38(3):421-444. PubMed ID: 30120411
[TBL] [Abstract][Full Text] [Related]
8. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
Huss WJ; Gray DR; Greenberg NM; Mohler JL; Smith GJ
Cancer Res; 2005 Aug; 65(15):6640-50. PubMed ID: 16061644
[TBL] [Abstract][Full Text] [Related]
10. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
[TBL] [Abstract][Full Text] [Related]
11. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
12. Effects of vitamin C on androgen receptor mediated actions in human prostate adenocarcinoma cell line LAPC-4.
Wang MH; Abreu-Delgado Y; Young CY
Urology; 2003 Jul; 62(1):167-71. PubMed ID: 12837460
[TBL] [Abstract][Full Text] [Related]
13. Hedgehog overexpression leads to the formation of prostate cancer stem cells with metastatic property irrespective of androgen receptor expression in the mouse model.
Chang HH; Chen BY; Wu CY; Tsao ZJ; Chen YY; Chang CP; Yang CR; Lin DP
J Biomed Sci; 2011 Jan; 18(1):6. PubMed ID: 21241512
[TBL] [Abstract][Full Text] [Related]
14. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
Sabnis NG; Miller A; Titus MA; Huss WJ
Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
[TBL] [Abstract][Full Text] [Related]
15. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Agoulnik IU; Weigel NL
J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
[TBL] [Abstract][Full Text] [Related]
17. Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.
Liu X; Chen X; Rycaj K; Chao HP; Deng Q; Jeter C; Liu C; Honorio S; Li H; Davis T; Suraneni M; Laffin B; Qin J; Li Q; Yang T; Whitney P; Shen J; Huang J; Tang DG
Oncotarget; 2015 Sep; 6(27):23959-86. PubMed ID: 26246472
[TBL] [Abstract][Full Text] [Related]
18. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
Mitsiades N; Sung CC; Schultz N; Danila DC; He B; Eedunuri VK; Fleisher M; Sander C; Sawyers CL; Scher HI
Cancer Res; 2012 Dec; 72(23):6142-52. PubMed ID: 22971343
[TBL] [Abstract][Full Text] [Related]
19. Interrogating androgen receptor function in recurrent prostate cancer.
Zhang L; Johnson M; Le KH; Sato M; Ilagan R; Iyer M; Gambhir SS; Wu L; Carey M
Cancer Res; 2003 Aug; 63(15):4552-60. PubMed ID: 12907631
[TBL] [Abstract][Full Text] [Related]
20. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
